Insurers Making It Harder to Treat Opioid Addiction
Insurers Making It Harder to Treat Opioid Addiction

Insurers Making It Harder to Treat Opioid Addiction

Insurance rules that limit access to the addiction treatment medication buprenorphine may be worsening the U.S. opioid epidemic.

HealthDay News


FRIDAY, Feb. 15, 2019 (HealthDay News) -- Insurance rules that limit access to the addiction treatment medication buprenorphine may be worsening the U.S. opioid epidemic, a new study suggests.

"Buprenorphine is a safe and effective treatment that decreases deaths due to opioids and stops heroin and other opioid use. People on buprenorphine are able to get their lives back together," said study co-author Dr. Todd Korthuis. He's chief of the addiction medicine section at Oregon Health and Science University (OHSU) in Portland.

"Medicare insurance companies are making it increasingly difficult to prescribe buprenorphine, while making it easy to prescribe opioid pain medications that contributed to the opioid epidemic," he said in an OHSU news release.

For the study, the researchers analyzed Medicare Part D prescription drug plan data and found that the growing use of pre-authorization requirements increasingly limited use of buprenorphine among Medicare beneficiaries between 2007 and 2018.

Insurers commonly use pre-authorization requirements to manage or limit access to certain drugs to control costs.

In 2007, nearly 90 percent of insurance plans offered buprenophine without restriction, but that number had shrunk to 35 percent by 2018. Over that same period, the proportion of plans that covered prescription opioids (such as OxyContin) with no restrictions ranged from 93 percent to 100 percent.

"The reasons for restrictions on buprenorphine might reflect inaccurate perceptions of drug risk, societal norms related to the stigma of addiction, or financial considerations," the authors wrote.

The findings appear in a research letter published Feb. 12 in the Journal of the American Medical Association.

Buprenorphine eases withdrawal symptoms and pain, and is one of three medicines approved by the U.S. Food and Drug Administration for treating opioid use disorder.

According to study author Daniel Hartung, "Access to buprenorphine is vital within the Medicare program because Medicare has not historically covered methadone, which is the other [anti-opioid drug] indicated for opioid use disorder." Hartung is an associate professor at OHSU/Oregon State University College of Pharmacy.

Medications such as buprenorphine are an effective way to treat opioid addiction, according to the U.S. Substance Abuse and Mental Health Services Administration.

Korthuis explained that "many people still believe that medication treatment isn't really recovery. Overwhelming scientific evidence supports that medicines like buprenorphine are far more successful and safer than abstinence-only approaches. Buprenorphine saves lives. Abstinence-based approaches don't."

SOURCE: Oregon Health and Science University, news release, Feb. 12, 2019

Copyright © 2019 HealthDay. All rights reserved.

ADVERTISEMENT

How Inequity Gets Built Into America’s Vaccination System

People eligible for the coronavirus vaccine are running up against barriers that are designed into the very systems meant to serve those most at risk of dying of the disease.

Prevention & Screenings

Vape Sellers Are Using Popular Music Videos to Promote E-Cigarettes to Young People – and It’s Working

Teens and young adults spend several hours a day looking at their phones and watching videos, many of which might contain product placements for vaping.

Your Health

How to Get Prior Authorization for Your Patients

92% of doctors report that prior authorizations cause delays in patient care

Created With Support